Table 2

Efficacy parameters in treatment and placebo groups during study follow-up

Outcome marker and time point1,25(OH)2D3PlaceboP value
n2218
AUC C-peptide (nmol/l × 120 min)
    Baseline90.8 ± 30.398.1 ± 33.00.47
    Month 976.3 ± 46.677.9 ± 37.70.91
    Month 1858.4 ± 47.758.0 ± 33.70.98
Fasting C-peptide (nmol/l)
    Baseline0.33 ± 0.120.34 ± 0.130.74
    Month 90.27 ± 0.210.25 ± 0.160.77
    Month 180.19 ± 0.180.22 ± 0.150.66
Peak C-peptide (nmol/l)
    Baseline1.00 ± 0.371.10 ± 0.360.36
    Month 90.79 ± 0.470.85 ± 0.390.71
    Month 180.66 ± 0.520.63 ± 0.340.86
A1C (%)
    Baseline8.4 ± 2.18.3 ± 1.60.82
    Month 96.3 ± 0.66.0 ± 0.70.13
    Month 186.1 ± 0.66.3 ± 0.80.51
Daily insulin dose (IU/day)
    Baseline24.9 ± 12.624.6 ± 8.90.94
    Month 926.5 ± 13.125.8 ± 13.90.87
    Month 1835.6 ± 19.234.9 ± 18.10.92
  • Data are means ± SD.